MA43724A - Molécules bispécifiques de cellules t activées par une protéase - Google Patents
Molécules bispécifiques de cellules t activées par une protéaseInfo
- Publication number
- MA43724A MA43724A MA043724A MA43724A MA43724A MA 43724 A MA43724 A MA 43724A MA 043724 A MA043724 A MA 043724A MA 43724 A MA43724 A MA 43724A MA 43724 A MA43724 A MA 43724A
- Authority
- MA
- Morocco
- Prior art keywords
- cells
- bispecific molecules
- protease activated
- protease
- activated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16161740 | 2016-03-22 | ||
| PCT/EP2017/056556 WO2017162587A1 (fr) | 2016-03-22 | 2017-03-20 | Molécules bispécifiques de cellules t activées par une protéase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43724A true MA43724A (fr) | 2018-11-28 |
| MA43724B1 MA43724B1 (fr) | 2023-06-28 |
Family
ID=55646332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43724A MA43724B1 (fr) | 2016-03-22 | 2017-03-20 | Molécules bispécifiques de cellules t activées par une protéase |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3433280B1 (fr) |
| KR (1) | KR102444614B1 (fr) |
| CN (1) | CN108884170A (fr) |
| AR (2) | AR107946A1 (fr) |
| AU (1) | AU2017237376B2 (fr) |
| CA (1) | CA3012422A1 (fr) |
| CO (1) | CO2018007556A2 (fr) |
| CR (1) | CR20180453A (fr) |
| MA (1) | MA43724B1 (fr) |
| PE (1) | PE20181891A1 (fr) |
| PT (1) | PT3433280T (fr) |
| SG (1) | SG11201808085WA (fr) |
| WO (1) | WO2017162587A1 (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3770168A1 (fr) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions et procédés de reprogrammation tcr utilisant des protéines de fusion |
| EP3297672B1 (fr) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Protéines trispécifiques de liaison et méthodes d'utilisation |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| CA3041279A1 (fr) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Domaine de liaison a l'antigene et polypeptide comprenant une section de transport |
| EP3585817A4 (fr) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | Compositions et procédés de traitement du cancer |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3078969A1 (fr) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Proteines trispecifiques et methodes d'utilisation |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| KR20250134208A (ko) * | 2017-11-28 | 2025-09-09 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드 |
| KR20200089312A (ko) * | 2017-11-28 | 2020-07-24 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
| KR20260039804A (ko) | 2017-12-21 | 2026-03-20 | 아뮤닉스 파마슈티컬스, 인크. | 유리 세그먼트 및 이것을 포함하는 결합 조성물 |
| CR20200391A (es) * | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
| WO2019222275A2 (fr) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions et procédés de reprogrammation de tcr utilisant des protéines de fusion inductibles |
| MX2020012217A (es) * | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| EP3807312A4 (fr) | 2018-05-30 | 2022-07-20 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprenant un domaine de liaison à l'aggrécane et une fraction de transport |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| CN112930199B (zh) * | 2018-07-24 | 2024-08-13 | 恺兴生命科技(上海)有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| WO2020023702A1 (fr) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EA202191338A1 (ru) * | 2018-11-16 | 2021-08-10 | Селджин Корпорейшн | Улучшенный способ производства т-клеток |
| CN113603783B (zh) | 2018-12-21 | 2022-07-12 | 浙江时迈药业有限公司 | 蛋白酶可切割的双特异性抗体及其用途 |
| MY204320A (en) | 2019-03-29 | 2024-08-22 | Mogam Inst Biomedical Res | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| WO2020232303A1 (fr) | 2019-05-14 | 2020-11-19 | Harpoon Therapeutics, Inc. | Protéines de liaison à epcam et méthodes d'utilisation |
| CN113905757B (zh) * | 2019-06-05 | 2026-01-13 | 中外制药株式会社 | 抗体切割位点结合分子 |
| EP3981428A4 (fr) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | Substrat de protéase et polypeptide comprenant une séquence de clivage de protéase |
| CN114341189A (zh) * | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| EP3999544A4 (fr) * | 2019-07-19 | 2023-08-09 | Wuxi Xdc Singapore Private Limited | Complexe polypeptidique pour conjugaison et son utilisation |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| CN115943210A (zh) | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | 配体结合融合蛋白 |
| WO2021207657A1 (fr) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions contenant des anticorps activables |
| CN116096754A (zh) | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| MX2022013920A (es) * | 2020-05-07 | 2022-11-30 | Phanes Therapeutics Inc | Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. |
| TW202214704A (zh) * | 2020-06-19 | 2022-04-16 | 瑞士商赫孚孟拉羅股份公司 | 蛋白酶活化t細胞雙特異性抗體 |
| CN115916830A (zh) * | 2020-06-25 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 抗cd3/抗cd28双特异性抗原结合分子 |
| WO2022170619A1 (fr) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anticorps anti-cd3 et leurs méthodes d'utilisation |
| US20230174995A1 (en) * | 2021-10-15 | 2023-06-08 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
| PE20241343A1 (es) * | 2021-10-15 | 2024-07-03 | Cytomx Therapeutics Inc | Complejo polipeptidico activable |
| AR128876A1 (es) * | 2022-03-28 | 2024-06-19 | Hoffmann La Roche | Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados |
| WO2023192973A1 (fr) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Molécules multispécifiques activables et leurs méthodes d'utilisation |
| IL316892A (en) | 2022-05-11 | 2025-01-01 | Regeneron Pharma | Multispecific proprotein binding molecules and their uses |
| WO2023222580A1 (fr) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Nouveaux anticorps masqués |
| CN116724057A (zh) * | 2022-11-28 | 2023-09-08 | 浙江时迈药业有限公司 | 蛋白酶可切割的重组双特异性抗体和组合物及其用途 |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| CN116462768B (zh) * | 2023-06-13 | 2023-09-22 | 浙江时迈药业有限公司 | 针对folr1的双特异性抗体及其用途 |
| EP4761818A1 (fr) * | 2023-08-18 | 2026-06-24 | F. Hoffmann-La Roche AG | Molécules de liaison à un domaine fc activables par protéase |
| WO2025199278A2 (fr) * | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Molécules de liaison à l'antigène multispécifiques masquées avec agents de liaison clivables |
| WO2026002279A1 (fr) * | 2024-06-28 | 2026-01-02 | Vibrant Pharma Limited | Peptide de masque, substrat clivable, anticorps multispécifiques et leurs utilisations |
| WO2026067689A1 (fr) * | 2024-09-28 | 2026-04-02 | 浙江道尔生物科技有限公司 | Médicament à base de protéine spécifiquement activée par une tumeur et son utilisation |
| WO2026090492A1 (fr) * | 2024-10-24 | 2026-04-30 | Xilio Development, Inc. | Agent de mise en contact cellulaire activés par une tumeur et leurs méthodes d'utilisation |
| WO2026107307A1 (fr) * | 2024-11-15 | 2026-05-21 | Hinge Bio, Inc. | Constructions tétraédriques se liant au folate et à cd3 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (de) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Ohrring |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
| EP0590058B1 (fr) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | ANTICORP HUMANISE specifique pour heregulin |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (fr) | 1992-02-06 | 1993-08-19 | L.L. Houston | Proteine fixatrice biosynthetique pour marqueur du cancer |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999029888A1 (fr) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanisation d'anticorps murins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2005100402A1 (fr) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anticorps anti-p-selectine |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| BRPI0607315B1 (pt) | 2005-02-07 | 2022-05-17 | Roche Glycart Ag | Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra |
| EP2322560B1 (fr) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anticorps anti-mésothéline |
| EP3663318A1 (fr) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2014004549A2 (fr) * | 2012-06-27 | 2014-01-03 | Amgen Inc. | Protéines de liaison anti-mésothéline |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) * | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| WO2014151910A1 (fr) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Anticorps hétérodimères bispécifiques |
| KR102813816B1 (ko) * | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| WO2015048272A1 (fr) * | 2013-09-25 | 2015-04-02 | Amgen Inc. | Anticorps v-c-fc-v-c |
| CA2955947A1 (fr) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps |
| EP2982692A1 (fr) * | 2014-08-04 | 2016-02-10 | EngMab AG | Anticorps bispécifiques contre la CD3epsilon et BCMA |
| WO2016077505A2 (fr) * | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Compositions de conjugués xten ciblés et leurs procédés de fabrication |
| ES2808853T3 (es) * | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| WO2016146894A1 (fr) * | 2015-03-17 | 2016-09-22 | Tilt Biotherapeutics Oy | Adénovirus oncolytiques codant pour des anticorps bi-spécifiques et méthodes et utilisations associées |
-
2017
- 2017-03-20 WO PCT/EP2017/056556 patent/WO2017162587A1/fr not_active Ceased
- 2017-03-20 CA CA3012422A patent/CA3012422A1/fr active Pending
- 2017-03-20 AU AU2017237376A patent/AU2017237376B2/en active Active
- 2017-03-20 CR CR20180453A patent/CR20180453A/es unknown
- 2017-03-20 EP EP17711223.2A patent/EP3433280B1/fr active Active
- 2017-03-20 MA MA43724A patent/MA43724B1/fr unknown
- 2017-03-20 PT PT177112232T patent/PT3433280T/pt unknown
- 2017-03-20 KR KR1020187027293A patent/KR102444614B1/ko active Active
- 2017-03-20 PE PE2018001324A patent/PE20181891A1/es unknown
- 2017-03-20 CN CN201780018328.8A patent/CN108884170A/zh active Pending
- 2017-03-20 SG SG11201808085WA patent/SG11201808085WA/en unknown
- 2017-03-22 AR ARP170100708A patent/AR107946A1/es unknown
-
2018
- 2018-07-18 CO CONC2018/0007556A patent/CO2018007556A2/es unknown
-
2020
- 2020-11-24 AR ARP200103258A patent/AR120543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180128407A (ko) | 2018-12-03 |
| AR107946A1 (es) | 2018-06-28 |
| PT3433280T (pt) | 2023-06-15 |
| CA3012422A1 (fr) | 2017-09-28 |
| CR20180453A (es) | 2018-12-05 |
| EP3433280B1 (fr) | 2023-04-19 |
| EP3433280A1 (fr) | 2019-01-30 |
| AU2017237376B2 (en) | 2024-03-07 |
| BR112018016281A2 (pt) | 2019-01-02 |
| AU2017237376A1 (en) | 2018-08-02 |
| AR120543A2 (es) | 2022-02-23 |
| CN108884170A (zh) | 2018-11-23 |
| SG11201808085WA (en) | 2018-10-30 |
| MA43724B1 (fr) | 2023-06-28 |
| WO2017162587A1 (fr) | 2017-09-28 |
| PE20181891A1 (es) | 2018-12-11 |
| CO2018007556A2 (es) | 2018-07-31 |
| KR102444614B1 (ko) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| IL263690A (en) | Purification of multispecific antibodies | |
| EP3419667A4 (fr) | Molécules multi-spécifiques | |
| EP3322803A4 (fr) | Synthèse enzymatique du d-tagatose | |
| DK3608337T3 (da) | Bispecifikke T-celleaktiverende antigenbindende molekyler | |
| EP3508222A4 (fr) | Médicament pour éliminer des cellules vieillissantes | |
| EP3332288A4 (fr) | Ensembles formant dispositifs électrochromes | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| EP3320082A4 (fr) | Administration de substances à des cellules anucléées | |
| EP3416690A4 (fr) | Aptamère bispécifique | |
| DK3131928T4 (da) | Trifunktionel antigen-bindende molekyle | |
| PT3097121T (pt) | Moléculas de anticorpo contra pd-1 e suas utilizações | |
| IL272851A (en) | Methods of using dipivefrin | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| EP3360010A4 (fr) | Source accordable de bi-photons | |
| EP3406336A4 (fr) | Nanofeuille de type structure c ur-écorce | |
| DK3242685T3 (da) | Cxcr4-bindende molekyler | |
| EP3359650A4 (fr) | Activation et expansion de cellules t | |
| HUE064252T2 (hu) | Antigénkötõ fehérjék töltött mélységi szûrése | |
| LT3237432T (lt) | Baltymo gamyba | |
| EP3411040A4 (fr) | Petites molécules pour la prolifération de cellules satellites de souris | |
| DK3283210T3 (da) | Fremgangsmåde | |
| EP3331988A4 (fr) | Reprogrammation chimique pour générer des cellules neuronales | |
| BR112016019822A2 (pt) | Determinação enzimática de hba1c | |
| IT201600130313A1 (it) | Struttura portante di veicolo |